SCHEMBL23168775

SCHEMBL23168775

Cc1ccc(Cn2cc(Oc3c(Cl)cc(N)cc3Cl)ccc2=O)cc1

nearest known ligand 0.43

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 4/20 0.43
▸ LMNA P02545 3/20 0.43
▸ ALDH1A1 P00352 2/20 0.43
▸ KDM4E B2RXH2 1/20 0.43
▸ CYP1A2 P05177 1/20 0.43
▸ POLB P06746 1/20 0.43
▸ CYP3A4 P08684 1/20 0.43
▸ CYP2D6 P10635 1/20 0.43
▸ CYP2C9 P11712 1/20 0.43
▸ CYP2C19 P33261 1/20 0.43
▸ HTT P42858 1/20 0.43
▸ NPBWR1 P48145 8/20 0.43
▸ MCHR1 Q99705 2/20 0.43
▸ TP53 P04637 1/20 0.39
▸ MEN1 O00255 1/20 0.37
▸ KMT2A Q03164 1/20 0.37
▸ NPSR1 Q6W5P4 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23168931 0.90 NPBWR1 (0.46) MAPTLMNANPBWR1MCHR1TP53
SCHEMBL23168940 0.88 MAPT (0.40) MAPTLMNATP53KMT2A
SCHEMBL24820993 0.88 MKNK1 (0.42) MAPTALDH1A1CYP3A4CYP2D6CYP2C9
SCHEMBL23168928 0.85 THRB (0.38) LMNAKDM4ENPBWR1
SCHEMBL23168951 0.85 MAPT (0.40) MAPTALDH1A1CYP1A2POLBCYP3A4
SCHEMBL31356395 0.85 MAPT (0.40) MAPTALDH1A1CYP1A2POLBCYP3A4
SCHEMBL23168745 0.85 KLKB1 (0.40) ALDH1A1NPBWR1MCHR1
SCHEMBL23168772 0.85 MAPT (0.43) MAPTLMNAALDH1A1KDM4ECYP1A2
SCHEMBL23168751 0.84 NPBWR1 (0.37) MAPTLMNAALDH1A1KDM4ECYP1A2
SCHEMBL23168773 0.84 MAPT (0.45) MAPTLMNAALDH1A1KDM4ECYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12617769-B2 Chemical compound as thyroid hormone beta receptor agonist and use thereof SUNSHINE LAKE PHARMA CO., LTD. (CN) 2026-05-05 — — US disclosed
US-20220411400-A1 CHEMICAL COMPOUND AS THYROID HORMONE BETA RECEPTOR AGONIST AND USE THEREOF SUNSHINE LAKE PHARMA CO., LTD. (CN) 2022-12-29 — — US disclosed
US-20220411400-A1 CHEMICAL COMPOUND AS THYROID HORMONE BETA RECEPTOR AGONIST AND USE THEREOF SUNSHINE LAKE PHARMA CO., LTD. (CN) 2022-12-29 — — US disclosed
EP-4036090-A1 CHEMICAL COMPOUND AS THYROID HORMONE BETA RECEPTOR AGONIST AND USE THEREOF Sunshine Lake Pharma Co., Ltd. (CN) 2022-08-03 — — EP disclosed
WO-2021057791-A1 CHEMICAL COMPOUND AS THYROID HORMONE BETA RECEPTOR AGONIST AND USE THEREOF 广东东阳光药业有限公司 2021-04-01 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220411400-A1 CHEMICAL COMPOUND AS THYROID HORMONE BETA RECEPTOR AGONIST AND USE THEREOF THRB, TSHR, THRA MAPT 1873/4885LMNA 3346/4885ALDH1A1 1134/4885
US-12617769-B2 Chemical compound as thyroid hormone beta receptor agonist and use thereof THRB, TSHR, THRA MAPT 2264/4885LMNA 1606/4885ALDH1A1 1340/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback